Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Jasco Pharmaceuticals has started a new research program in collaboration with North Carolina Central University (NCCU) in Durham, North Carolina, to develop pancreatic cancer therapeutics through a Pim kinase mechanism of action.
Subscribe to our email newsletter
Under this program, Jasco Pharma and NCCU are expected to combine the biological platform, tools and expertise at NCCU in the laboratory of Antonio Baines with Jasco Pharma’s proprietary selective Pim kinase inhibitors.
Jasco Pharma president Carmen Baldino said they are very excited to collaborate with NCCU and Professor Baines to better understand the role Pim kinases play in pancreatic cancer.
"The research will accelerate our ongoing Pim inhibitor program, progress the knowledge base in pancreatic cancer biology, and further elucidate strategies for the development of therapies targeting Pim kinases, which are increasingly becoming recognized as an important target class in oncology," Baldino said.